Press releasePRNewswire
Enliven Therapeutics
ELVN · NASDAQ
$41.25+$2.55 (+6.59%)TodayMarket closed ·
Prev close $38.70
Latest news
- Press releasePRNewswire
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
- Press releasePRNewswire
Enliven Therapeutics to Present at Upcoming Investor Conferences
- Press releasePRNewswire
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
- NewsVandana Singh
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
- Press releasePRNewswire
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
- Press releasePRNewswire
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- Press releasePRNewswire
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
- Press releasePRNewswire
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- NewsAvi Kapoor
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings
- NewsAvi Kapoor
Stitch Fix, Intel, KLA And Other Big Stocks Moving Higher On Thursday
- News
Enliven Therapeutics Presents Data From The Phase 1 Enable Clinical Trial Evaluating ELVN-001 In Patients With Previously Treated Chronic Myeloid Leukemia; Notes Encouraging Efficacy Data By 24 Weeks
- Press releasePRNewswire
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
- Press releasePRNewswire
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
- Press releasePRNewswire
Enliven Therapeutics to Present at Upcoming Investor Conferences
- Press releasePRNewswire
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
- Press releasePRNewswire
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
Enliven Therapeutics: Q4 Earnings Insights
- Press releasePRNewswire
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
- Press releasePRNewswire
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
- Press releaseGlobe Newswire
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
- NewsAvi Kapoor
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Neogen Posts Strong Q2 Earnings, Joins Astronics, Lockheed Martin, Constellation Brands And Other Big Stocks Moving Higher On Thursday
- NewsAvi Kapoor
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings
- Press releasePRNewswire
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
- Press releasePRNewswire
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
- Press releasePRNewswire
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
- Press releasePRNewswire
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
- Press releasePRNewswire
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
- Press releasePRNewswire
/C O R R E C T I O N -- Enliven Therapeutics, Inc./
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releasePRNewswire
Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting
- Press releasePRNewswire
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting
- NewsAvi Kapoor
Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday
- NewsAvi Kapoor
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.